Holen Sie sich die Stockscreener-App
24.98
0.22%
-15.84
Handel nachbörslich:
24.99
0.005
+0.02%
Schlusskurs vom Vortag:
$9.14
Offen:
$24.985
24-Stunden-Volumen:
0
Relative Volume:
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-13.29
EPS:
-1.88
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-2.04%
6M Leistung:
+10.95%
1J Leistung:
-15.87%
1-Tages-Spanne:
$24.98
$24.98
1-Wochen-Bereich:
$24.98
$24.98
52-Wochen-Spanne:
$24.98
$24.98
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Firmenname
Flexion Therapeutics, Inc.
Sektor
Telefon
781-305-7777
Adresse
10 Mall Road, Suite 301, Burlington
Vergleichen Sie FLXN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
24.98 | 0 | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
151.54 | 70.46B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.78B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.69 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.01 | 19.16B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.16 | 13.56B | 2.99B | 1.21B | 1.13B | 25.06 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-08-20 | Eingeleitet | Goldman | Neutral |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-29 | Eingeleitet | Credit Suisse | Outperform |
| 2020-06-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2019-12-27 | Bestätigt | The Benchmark Company | Buy |
| 2019-12-05 | Eingeleitet | Craig Hallum | Buy |
| 2019-11-25 | Eingeleitet | BTIG Research | Buy |
| 2019-05-09 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2019-01-04 | Bestätigt | Needham | Buy |
| 2019-01-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2018-06-28 | Eingeleitet | The Benchmark Company | Buy |
| 2017-10-09 | Bestätigt | Needham | Buy |
| 2017-08-24 | Eingeleitet | Northland Capital | Outperform |
| 2016-12-22 | Eingeleitet | Raymond James | Strong Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-07-21 | Eingeleitet | Lake Street | Buy |
| 2016-05-03 | Fortgesetzt | Wells Fargo | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-09-09 | Bestätigt | Needham | Buy |
Alle ansehen
Flexion Therapeutics, Inc. Aktie (FLXN) Neueste Nachrichten
Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy - The Globe and Mail
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program - The Manila Times
Musculoskeletal Pain Therapeutics Market Size in 7MM - openPR.com
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals Appoints William T. Andrews, MD, FACP as Chief Medical Officer - citybiz
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
Catalyst Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com India
Osteoarthritis Therapeutics Market Emerging Tech Trends to Watch from 2025 to 2032 - newstrail.com
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies - The Manila Times
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Knee osteoarthritis Market: Epidemiology, Therapies, - openPR.com
Musculoskeletal Pain Treatment Market Size in 7MM is expected - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Osteoarthritis Therapeutics Market Size Unlocking New Opportunities for Success As Revealed In New Report - WhaTech
Anti-Inflammatory Therapeutics Market Recent - openPR.com
Dollar Gains on US Economic News and Hawkish Bostic - The Globe and Mail
Musculoskeletal Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, - openPR.com
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
USDCAD Completes A Correction Within An Uptrend - The Globe and Mail
Neogen (NEOG) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Nio Stock: The EV Darling That Still Can’t Deliver Profits - The Globe and Mail
Cautious Optimism for Building Products Distribution Rising as Sustained Demand for New Residential Construction Expected - The Globe and Mail
Knee Osteoarthritis Pipeline: Over 50 Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301 - marketscreener.com
Flexion Therapeutics, Inc. Announces Executive Changes - MarketScreener
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - The Globe and Mail
I'm Buying This Nvidia-Backed AI Company Before It Explodes - The Globe and Mail
Osteoarthritis Treatment Market Trends and Forecast 2034 - openPR.com
Rivian's Autonomy Push Is Another Potential Failure - The Globe and Mail
Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Rocket Lab (RKLB) Q4 Earnings: What To Expect - The Globe and Mail
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & SuppliesDiversified Segment - The Globe and Mail
Armlogi Advances Supply Chain Solutions with Roadie, a UPS Company, Expanding Last-Mile Delivery Coverage to 97% of U.S. - The Globe and Mail
AMD Is Looking Like a No-Brainer Buy, Here's Why. - The Globe and Mail
Joint Pain Injections Market Set to Surge to $13.18 Billion by 2031 at a 7.7% CAGR - EIN News
3 Steel Stocks to Gain Strength as Tariffs Reshape the Market - The Globe and Mail
Week Ahead In Pharma (May 10- 14): FDA Decision, Data Readouts (RCKT, AVRO, FLXN, RARE, HRTX…) - RTTNews
CPRXCatalyst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Musculoskeletal Pain Therapeutics Market Size in the 7MM is expected to grow by 2034 and estimates DelveInsight - Barchart
Joint Pain Injections Market: Unleashing Growth Opportunities - openPR
[Expert View] Osteoarthritis Treatment Market Innovating Therapies for Joint Health Improvement | 20242033 - openPR
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
iBio Strengthens Board with Appointment of Two New Independent Directors - GlobeNewswire
PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration - Nature
Osteoarthritis Therapeutics Market Size, Report By 2034 - Precedence Research
Finanzdaten der Flexion Therapeutics, Inc.-Aktie (FLXN)
Es liegen keine Finanzdaten für Flexion Therapeutics, Inc. (FLXN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
8.43%
1.68%
Kapitalisierung:
|
Volumen (24h):